BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/7/2017 8:24:12 AM | Browse: 1423 | Download: 2292
Publication Name World Journal of Clinical Oncology
Manuscript ID 30372
Country United States
Received
2016-09-29 16:32
Peer-Review Started
2016-10-07 21:01
To Make the First Decision
2016-12-01 14:16
Return for Revision
2016-12-06 19:50
Revised
2016-12-20 21:21
Second Decision
2017-02-15 18:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-03-02 08:16
Articles in Press
2017-03-02 08:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-03-30 14:43
Publish the Manuscript Online
2017-04-07 08:24
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Frontier
Article Title Leptin signaling and cancer chemoresistance: Perspectives
Manuscript Source Invited Manuscript
All Author List Pierre V Candelaria, Antonio Rampoldi, Adriana Harbuzariu and Ruben R Gonzalez-Perez
Funding Agency and Grant Number
Funding Agency Grant Number
National Institute of Health (NIH)/National Cancer Institute (NCI) 1R41CA183399-01A1
Department of Defense (DOD), Congressionally Direct Medical Research Program (CDMRP) W81XWH-13-1-0382
Pilot Project Award from MSM (Morehouse School of Medicine)/Tuskegee University/University of Alabama in Birmingham (UAB) Cancer Center partnership 5U54CA118638
National Institute on Minority Health and Health Disparities (NIMHD) of NIH 5S21MD00101
Corresponding Author Ruben R Gonzalez-Perez, PhD, Professor, Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Hugh Gloster Bldg., Room 329, Atlanta, GA 30310, United States. rgonzalez@msm.edu
Key Words Obesity-related cancer; Cancer stem cells; Leptin; Chemoresistance; Breast cancer; Pancreatic cancer
Core Tip Obesity and its main mediator leptin, are implicated in many protumorigenic processes, with emerging evidence from both the literature and our work pointing to a significant role in the development of resistance to chemotherapies. Chemoresistance is a major concern in the field of cancer therapy as some cancers have no targeted therapies available. As obesity reaches epidemic proportions around the world, its impact on diseases like cancer and its treatment becomes more relevant. In this paper, we will discuss the current state of the literature regarding the influence of obesity and leptin on cancer treatment and the development of chemoresistance.
Publish Date 2017-04-07 08:24
Citation Candelaria PV, Rampoldi A, Harbuzariu A, Gonzalez-Perez RR. Leptin signaling and cancer chemoresistance: Perspectives. World J Clin Oncol 2017; 8(2): 106-119
URL http://www.wjgnet.com/2218-4333/full/v8/i2/106.htm
DOI http://dx.doi.org/10.5306/wjco.v8.i2.106
Full Article (PDF) WJCO-8-106.pdf
Full Article (Word) WJCO-8-106.doc
Manuscript File 30372-Review.docx
Answering Reviewers 30372-Answering reviewers.pdf
Audio Core Tip 30372-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 30372-Conflict-of-interest statement.pdf
Copyright License Agreement 30372-Copyright assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 30372-Grant application form(s).pdf
Supplementary Material Supplementary_Material_20160929102212.pdf
Peer-review Report 30372-Peer-review(s).pdf
Scientific Misconduct Check 30372-Scientific misconduct check.pdf
Scientific Editor Work List 30372-Scientific editor work list.pdf